CAS: 1477-19-6; (2-Ethylbenzofuran-3-yl)(4-Hydroxyphenyl)Methanone

该化合物是属于苯并苯的化学化合物,主要被确认为作为医药中间体和各种有机化合物合成物的应用.本扎罗内通常呈现晶状固体形式,其特点是芳香结构,有助于其稳定性和回活性.该化合物因其吸收紫外光的能力而有可能用于摄影保护,因此在化妆品配方中具有相关性.此外,它可能具有抗氧化性特性,可以对各种应用有益.然而,与许多有机化合物一样,它应该谨慎处理,因为如果吸收或管理不当,它可能会对健康造成危害.其溶性特征可能不同,在有机溶剂中往往比在水中更容易溶.

结构式图片

欧盟法规

REACH注册ECHA物质C&L通报REACH预注册

上下游产品

2-ethylbenzofuran 4-(benzyloxy)benzoic acid chloride (2-ethylbenzofuran-3-yl)(4-methoxyphenyl)methanone (4-acetoxy-phenyl)-(2-ethyl-benzofuran-3-yl)-ketonebenzbromarone Natriumbenzaronsulfat benzbromarone methyl ether benziodarone

合成工艺路线路线简述

    对甲氧基苯甲酰氯置于吡啶盐酸盐,四氯化锡体系中,用 甲苯 用作溶剂,化学反应 4.5H,反应生成苯扎隆
    参考文献:一种苯溴马隆杂质b的制备方法
    标题:一种苯溴马隆杂质b的制备方法
    摘要:本发明涉及一种苯溴马隆杂质b的制备方法,包括:先用2‑乙基苯并呋喃,对甲氧基苯甲酰氯,甲苯,无水四氯化锡生成有棕红色固体,加入冰水,盐酸调节ph值,然后加入甲苯萃取;过滤,减压浓缩除去甲苯,得黄色油状物中间体1;将中间体1,盐酸吡啶,甲苯装入反应瓶,将甲苯蒸干;然后将蒸馏装置改换成回流装置,加热,回流.待反应液冷却后,加入稀盐酸,然后加入甲苯萃取.抽滤,减压浓缩,得黄色固体中间体2;将冰醋酸,乙醇,溴化氢加入瓶中,搅拌加入中间体2,溴化钠搅拌.溶解完全后降温,滴加双氧水,过滤,湿品用制备液相分离,浓缩,得到苯溴马隆杂质b.

    海关参考信息

    专利信息


    专利号:US-9353057-B2
    优先权日:2003-12-30
    标 题:Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
    发明人:GALLOP MARK A; DAI XUEDONG; SCHEUERMAN RANDALL A; RAILLARD STEPHEN P; MANTHATI SURESH K; YAO FENMEI; PHAN THU; LUDWIKOW MARIA; PENG GE; BHAT SEEMA
    权利人:XENOPORT INC
    摘要:Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.

    专利号:US-11479577-B2
    优先权日:2016-05-18
    标题:Intermediates for the synthesis of bile acid derivatives, in particular of obeticholic acid
    发明人:WEYMOUTH-WILSON ALEXANDER; KOMSTA ZOFIA; WALLIS LAURA; EVANS TIMOTHY; DAVIES IEUAN; OTTER CARL; BATCHELOR RHYS
    权利人:NZP UK LTD
    摘要:The present invention relates to compounds which are intermediates in the synthesis of bile acid derivatives with pharmacological activity. The invention relates to compounds of general formula (I):wherein:, R1, R2, R3, R4, R5, R6 and Y are as defined herein.The compounds are intermediates in the synthesis of synthetic bile acids which are useful in the treatment of conditions such as liver disease. In addition, the invention relates to a method of synthesizing these intermediates and a method of preparing obeticholic acid and obeticholic acid analogues from the compounds of the invention.

    专利号:US-10711138-B2
    优先权日:2016-04-08
    标题:Intermediates and procedures for the synthesis of functional materials
    发明人:KIRSCH PEER; GUNST SUSANN
    权利人:MERCK PATENT GMBH
    摘要:The present invention relates to heteroaromatic compounds which have two different reactive groups, their use in the synthesis of asymmetrically substituted compounds, and synthesis processes in which the compounds according to the invention are reacted sequentially with two different compounds, whereby an asymmetrically substituted compound is formed.

    专利号:WO-0027627-A1
    优先权日:1998-11-12
    标题 :Aryloxime linkers in the solid-phase synthesis of 3-aminobenzisoxazoles
    发明人:WILEY MICHAEL ROBERT; LEPORE SALVATORE DONATO
    权利人:LILLY CO ELI; WILEY MICHAEL ROBERT; LEPORE SALVATORE DONATO
    摘要:In its first aspect, the invention is directed to a solid support mediated method for the synthesis of diverse polycyclic heterocycles according to general formula (V). A second aspect of the invention is directed to a solid support bound intermediate compound that optionally can be derivatized before a cyclization and displacement procedure provides a product. The intermediate is preferably stable to a wide range of chemical conditions thus allowing, if desired, for the chemical derivatization of the intermediate. A third aspect of the invention is directed to a library of polycyclic heterocycle compounds where said library contains a plurality of diverse library compounds of general formula (V). A fourth aspect of the invention is directed to a method for the synthesis of a library of diverse polycyclic heterocycles by the general method described. A fifth aspect of the invention is directed to an assay kit for the identification of lead compounds of the library described therein.

    专利号:US-6815214-B2
    优先权日:2000-12-29
    标 题 :Pharmaceutical uses and synthesis of diketopiperazines
    发明人:BOYCE JIM P; HOWBERT J JEFFRY; TABONE JOHN C
    权利人:CELLTECH R & D INC
    摘要:The synthesis of novel diketopiperazines, their use in inhibiting cellular events such as those involving NFK-α, NFK-β and in the treatment of inflammation events, a combinatorial library of diverse diketopiperazines and process for their synthesis as a library and as individual compounds. In particular novel diketopiperazines are disclosed including their synthesis and use in cellular events such as activation of the transcription factor, nuclear factor, TNF-α, TNF-β and also apoptosis.

    专利号:US-8618281-B2
    优先权日:2006-01-03
    标 题 :Geometric synthesis of porphyrin rods
    发明人:LINDSEY JONATHAN S; YU LIANHE; THAMYONGKIT PATCHANITA; BHISE ANIL D
    权利人:LINDSEY JONATHAN S; YU LIANHE; THAMYONGKIT PATCHANITA; BHISE ANIL D; UNIV NORTH CAROLINA STATE
    摘要:A method of making a compound of Formula I′ n ncomprises reacting a compound of the formula DLCHO, with a compound of the formulan n nto produce the compound of Formula I′. Methods of using the compounds are also described, particularly as intermediates for the synthesis of porphyrin rods, which porphyrin rods are in turn useful for (among other things) the production of molecular memory devices.
    友顺精细化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.usunfc.com
    企业联系电话:025-84574075;84574691👤
    📞友顺精细化工有限公司 ⚠️参考联系方式
    联系人:销售部
    电话:025-84574075;84574691

    传真:025-84574930
    邮箱:sales@usunfc.com
    通信地址: 南京市建邺区云龙山路89号龙湖时代上城1栋1005室
    邮编: 210019
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:南京市建邺区云龙山路89号龙湖时代上城1栋1005室
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    上海丰瑞医药科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.foraidpharma.com
    企业联系电话:021-50870636👤
    📞上海丰瑞医药科技有限公司 ⚠️参考联系方式
    联系人:卞先生
    电话:021-50870636
    手机:15021301021
    传真:021-50870637
    邮箱:550937941@qq.com
    通信地址: 上海市张江高科技产业东区瑞庆路526号4幢402室
    邮编: 201210
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:上海市张江高科技产业东区瑞庆路526号4幢402室
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    宁波斯迈克制药有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.smart-pharm.com
    企业联系电话:0574-86221816👤
    📞宁波斯迈克制药有限公司 ⚠️参考联系方式
    联系人:张海波
    电话:0574-86221816
    手机:13957841334
    传真:0574-86222227
    邮箱:smart@smart-pharm.com;carolyn@smart-pharm.com
    通信地址: 浙江省宁波市北仑区小港镇义成路1号
    邮编: 315803
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:浙江省宁波市北仑区小港镇义成路1号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    江西金丰药业有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.jxjfpharma.com
    企业联系电话:0793-8616088👤
    📞江西金丰药业有限公司 ⚠️参考联系方式
    联系人:杨悦宁
    电话:0793-8616088
    手机:15757561853
    传真:0793-8616725
    邮箱:yangyuening@jxjfpharma.com
    通信地址: 江西省铅山县工业园区19路
    邮编:
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:江西省铅山县工业园区19路
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Kaufmann P, Török M, Hänni A, Roberts P, Gasser R, Krähenbühl S. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology. 2005 Apr;41(4):925-35. German. German. German. Klin Wochenschr. 1988 Feb 15;66(4):160-6. French. German. German. French. German. doi: 10.1371/journal.pone.0034806. Epub 2012 Apr 24.
    20: Rana P, Will Y, Nadanaciva S, Jones LH. Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. Bioorg Med Chem Lett. 2016 Aug 15;26(16):4003-6. doi: 10.1016/j.bmcl.2016.06.088. Epub 2016 Jun 30.

    合成参考文献


    参考文献:10.1021/tx900326k
    摘要:Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A. Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chem Res Toxicol. 2010 Jan;23(1):171–83.
    参考文献:10.1007/978-3-642-00663-0_11
    摘要:Pessayre D, Mansouri A, Berson A, Fromenty B. Mitochondrial involvement in drug-induced liver injury. Handb Exp Pharmacol. 2010;(196):311–65. doi: 10.1007/978-3-642-00663-0_11.
    参考文献:10.1016/j.drudis.2011.05.007
    摘要:Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today. 2011 Aug;16(15-16):697–703. doi: 10.1016/j.drudis.2011.05.007.
    参考文献:10.1021/jm3014635
    摘要:Gordon CP, Williams P, Chan WC. Attenuating Staphylococcus aureus virulence gene regulation: a medicinal chemistry perspective. J Med Chem. 2013 Feb 27;56(4):1389–404.
    摘要:Archives Internationales de Pharmacodynamie et de Therapie., 154(94), 1965 []
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知